Company intelligence / Profile preview

Biosuccess Biotech Co., Ltd.

San Jose, California, United Statesbiosuccessbiotech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company’s lead program has reached Phase II clinical development. A notable clinical trial involved PD‑616 in combination with low-dose cytarabine for untreated or relapsed/refractory AML or high-risk MDS, but this study was terminated at the Phase 1/2 stage. The company continues to focus on breakthrough medicines in hematology/oncology and neuroscience.

Therapeutic areas: HematologyOncology
Modalities: Small molecules (notably phorbol esters such as Phorbol 12-myristate 13-acetate)
Industry: Biotech

Beyond the preview

Go deeper on Biosuccess Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosuccess Biotech Co., Ltd..

Explore the full profile